GB0100551D0 - Protein - Google Patents

Protein

Info

Publication number
GB0100551D0
GB0100551D0 GBGB0100551.1A GB0100551A GB0100551D0 GB 0100551 D0 GB0100551 D0 GB 0100551D0 GB 0100551 A GB0100551 A GB 0100551A GB 0100551 D0 GB0100551 D0 GB 0100551D0
Authority
GB
United Kingdom
Prior art keywords
fusion protein
nucleic acid
construct
sequence encoding
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0100551.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Priority to US09/756,283 priority Critical patent/US6942853B2/en
Priority to GBGB0100551.1A priority patent/GB0100551D0/en
Publication of GB0100551D0 publication Critical patent/GB0100551D0/en
Priority to AU2002219345A priority patent/AU2002219345B2/en
Priority to PCT/GB2002/000068 priority patent/WO2002055098A2/en
Priority to AT02729440T priority patent/ATE293169T1/de
Priority to JP2002555832A priority patent/JP4201253B2/ja
Priority to DE60203692T priority patent/DE60203692T2/de
Priority to EP02729440A priority patent/EP1349944B1/en
Priority to DK02729440T priority patent/DK1349944T3/da
Priority to ES02729440T priority patent/ES2240740T3/es
Priority to ZA2003/05237A priority patent/ZA200305237B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB0100551.1A 2001-01-09 2001-01-09 Protein Ceased GB0100551D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US09/756,283 US6942853B2 (en) 2001-01-09 2001-01-09 Latent fusion protein
GBGB0100551.1A GB0100551D0 (en) 2001-01-09 2001-01-09 Protein
ES02729440T ES2240740T3 (es) 2001-01-09 2002-01-09 Metodo para proporcionar latencia a agentes farmaceuticamente activos.
AT02729440T ATE293169T1 (de) 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
PCT/GB2002/000068 WO2002055098A2 (en) 2001-01-09 2002-01-09 Latency associated peptide for providing latency to pharmaceutically active proteins
AU2002219345A AU2002219345B2 (en) 2001-01-09 2002-01-09 Latency associated peptide for providing latency to pharmaceutically active proteins
JP2002555832A JP4201253B2 (ja) 2001-01-09 2002-01-09 薬学的活性物質に潜在性を提供する方法
DE60203692T DE60203692T2 (de) 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
EP02729440A EP1349944B1 (en) 2001-01-09 2002-01-09 Latency associated peptide of tgf-beta for providing latency to pharmaceutically active proteins
DK02729440T DK1349944T3 (da) 2001-01-09 2002-01-09 Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
ZA2003/05237A ZA200305237B (en) 2001-01-09 2003-07-07 Latency associated peptide for providing latency to pharmaceutically active proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/756,283 US6942853B2 (en) 2001-01-09 2001-01-09 Latent fusion protein
GBGB0100551.1A GB0100551D0 (en) 2001-01-09 2001-01-09 Protein

Publications (1)

Publication Number Publication Date
GB0100551D0 true GB0100551D0 (en) 2001-02-21

Family

ID=26245544

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0100551.1A Ceased GB0100551D0 (en) 2001-01-09 2001-01-09 Protein

Country Status (10)

Country Link
US (1) US6942853B2 (https=)
EP (1) EP1349944B1 (https=)
JP (1) JP4201253B2 (https=)
AT (1) ATE293169T1 (https=)
AU (1) AU2002219345B2 (https=)
DE (1) DE60203692T2 (https=)
DK (1) DK1349944T3 (https=)
ES (1) ES2240740T3 (https=)
GB (1) GB0100551D0 (https=)
WO (1) WO2002055098A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
CN101044154A (zh) * 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
WO2007044321A2 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
DE102006009324A1 (de) 2006-03-01 2007-09-06 Dr.Ing.H.C. F. Porsche Ag Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts
EP2091568A2 (en) * 2006-10-31 2009-08-26 East Carolina University Fusion proteins comprising a anti-inflammatory cytokine and an antigen for treatment of immune disorders
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
FR2932190A1 (fr) * 2008-06-10 2009-12-11 Commissariat Energie Atomique Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
EP2878308B1 (en) * 2013-12-02 2018-10-31 Thomas Harder Agents and methods for the suppression of T cell activation
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
ES2780274A1 (es) 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
WO2021207669A1 (en) * 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
CA2003886A1 (en) 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
EP0502036B1 (en) 1989-11-22 1995-12-20 Genentech, Inc. Latency associated peptide and uses therefor
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
WO1994026892A1 (en) 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
CA2151547C (en) 1994-06-10 2010-10-12 Elliott A. Gruskin Recombinant chimeric proteins and methods of use thereof
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
AU7023798A (en) * 1997-04-30 1998-11-24 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
CA2345024C (en) 1998-10-07 2009-05-19 Stryker Corporation Modified tgf-.beta. superfamily proteins
CA2421582A1 (en) * 2000-09-11 2002-03-21 The Trustees Of Columbia University In The City Of New York Combinatorial fluorescence energy transfer tags and uses thereof

Also Published As

Publication number Publication date
ATE293169T1 (de) 2005-04-15
JP2004520031A (ja) 2004-07-08
AU2002219345B2 (en) 2006-03-16
EP1349944B1 (en) 2005-04-13
US6942853B2 (en) 2005-09-13
JP4201253B2 (ja) 2008-12-24
DE60203692T2 (de) 2006-03-02
EP1349944A2 (en) 2003-10-08
DE60203692D1 (de) 2005-05-19
US20020151478A1 (en) 2002-10-17
WO2002055098A3 (en) 2002-11-21
WO2002055098A2 (en) 2002-07-18
ES2240740T3 (es) 2005-10-16
DK1349944T3 (da) 2005-07-25

Similar Documents

Publication Publication Date Title
GB0100551D0 (en) Protein
WO2001083782A3 (en) Novel proteases
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
AU3368497A (en) Human dnase i hyperactive variants
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
AU2003222717A8 (en) Streptavidin-binding peptide
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
IL184227A0 (en) Biologically active peptides
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2004053117A3 (en) Serine protease
DE60015559D1 (de) Sentrin-spezifische menschliche protease senp1
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE69730967D1 (en) Human dnase ii
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
WO2000052147A3 (en) Bacterial prolyl peptidases and methods of use
WO2003025182A1 (fr) Adn de surexpression d'une hormone de croissance et utilisation
WO2001094417A3 (en) Novel human seven transmembrane proteins and polynucleotides encoding the same
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2004089980A3 (en) Therapeutic cancer vaccine
TW200611913A (en) Biologically active peptides (Ⅲ)
WO2002008393A3 (en) Serine protease from yersinia enterocolitica
JP2004201547A5 (https=)

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)